



# Patient Involvement in an Assessment of Interventions for Hyperhidrosis

Ros Wade,<sup>1</sup> Stephen Rice,<sup>2</sup> Eoin Moloney,<sup>2</sup> Julija Stoniute,<sup>2</sup> Alison M Layton,<sup>3</sup> Nick J Levell,<sup>4</sup> Gerard Stansby,<sup>5</sup> Julie Jones-Diette,<sup>1</sup> Alexis Llewellyn,<sup>1</sup> Kath Wright,<sup>1</sup> Dawn Craig,<sup>2</sup> Nerys Woolacott<sup>1</sup>

<sup>1</sup>Centre for Reviews and Dissemination, University of York, <sup>2</sup>Institute of Health & Society, Newcastle University, <sup>3</sup>Harrogate and District NHS Foundation Trust, <sup>4</sup>Norfolk and Norwich University Hospital NHS Foundation Trust, <sup>5</sup>The Newcastle upon Tyne Hospitals NHS Foundation Trust

## BACKGROUND AND OBJECTIVES

Primary hyperhidrosis has no discernible cause and is characterised by uncontrollable excessive and unpredictable sweating, which occurs at rest, regardless of temperature. The symptoms of hyperhidrosis can significantly affect quality of life, and can lead to social embarrassment, loneliness, anxiety and depression. There is substantial variation in the secondary care treatment of hyperhidrosis and uncertainty regarding optimal patient management.

The objective of this Health Technology Assessment was to review the evidence and establish the expected value of undertaking additional research into effective interventions for the management of primary hyperhidrosis in secondary care.

## RESULTS

At the end-of-project workshop, the systematic review finding that botulinum toxin injections significantly improved axillary hyperhidrosis symptoms in the short to medium term was supported; there was consensus amongst patients and clinicians that botulinum toxin injections were very effective. The advisors did not consider that further research on iontophoresis for axillary hyperhidrosis would be worthwhile; despite the lack of trial evidence, they believed iontophoresis was moderately effective in some patients. However, they agreed that future trials of treatments for hyperhidrosis of the axilla should compare new treatments against botulinum toxin injections, as an established effective treatment.

The advisors agreed that a trial of botulinum toxin injections (plus anaesthetic) versus iontophoresis for palmar hyperhidrosis would be useful, and that outcomes should include long term impairment of hand sensitivity and pain of botulinum toxin administration.

Patients and clinicians were satisfied with the sequence of treatments identified as being cost-effective for axillary hyperhidrosis in the modeling exercise: iontophoresis, botulinum toxin injections, anticholinergic medication, curettage, endoscopic thoracic sympathectomy.

All patient advisors agreed that the Hyperhidrosis Quality of Life Index (HidroQoL<sup>©</sup>)

## METHODS

The assessment included a systematic review and economic model, including value of information analysis. Patients, dermatologists, a vascular surgeon and a specialist nurse (who set up the Hyperhidrosis UK support group) provided advice at various stages of the project, including initial team meetings and during protocol development. The results of the review and economic analyses were discussed with a small group of patients and other advisors at an end-of-project workshop to incorporate their perspective in the interpretation of results and the prioritisation of research recommendations.



## PATIENT OR HEALTHCARE CONSUMER INVOLVEMENT

Capturing the perspectives of patients with hyperhidrosis was an important part of the research. Their involvement in the end-of-project workshop was informative when interpreting the results of the assessment and prioritising research recommendations. Patient advisors also commented on a summary article for patients, which was disseminated via the Hyperhidrosis UK support group.

was superior to other tools commonly used in hyperhidrosis research (Hyperhidrosis Disease Severity Scale, Dermatology Life Quality Index and Hyperhidrosis Quality of Life Questionnaire) for assessing quality of life. They commented that it covers everything important to patients with hyperhidrosis and is easy to complete. Patients considered that the HidroQoL<sup>©</sup> tool should be the primary outcome in future studies assessing the effectiveness of interventions for hyperhidrosis and that measuring the actual amount of sweat produced should only be considered as a secondary outcome.

## CONCLUSIONS

Patients and clinicians considered the key findings of the systematic review and economic analyses to be appropriate.

The advisors helped prioritise research recommendations to fill gaps in the evidence base.

All patients were in agreement about which quality of life tool they preferred for use in future hyperhidrosis research.

### References

Wade R, Rice S, Llewellyn A, Moloney E, Jones-Diette J, Stoniute J, Wright K, Layton AM, Levell NJ, Stansby G, Craig D, Woolacott N. Interventional management of hyperhidrosis: a systematic review, meta-analysis, cost-effectiveness analysis and value of information analysis. *Health Technology Assessment* 2017;21(80):1-280. doi: 10.3310/hta21800.

### Study registration

The protocol was registered on PROSPERO (registration number: CRD42015027803).

### Funding details

This project was funded by the NIHR HTA Programme (project number 14/211/02).

The views and opinions expressed are those of the authors and do not necessarily reflect those of the NIHR HTA Programme or the Department of Health.